| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2012.660250 |
| P698 | PubMed publication ID | 22324973 |
| P2093 | author name string | G Ralph Corey | |
| Zeina A Kanafani | |||
| P2860 | cites work | Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. | Q37417427 |
| Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature | Q37824612 | ||
| Antivirulence potential of TR-700 and clindamycin on clinical isolates of Staphylococcus aureus producing phenol-soluble modulins. | Q38282658 | ||
| Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines | Q39798802 | ||
| Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges | Q40334689 | ||
| Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain. | Q40336550 | ||
| In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. | Q41389487 | ||
| Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). | Q42024058 | ||
| Comparative In Vitro Activities of Torezolid (DA-7157) against Clinical Isolates of Aerobic and Anaerobic Bacteria in South Korea | Q42111215 | ||
| Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. | Q43041506 | ||
| First outbreak of vancomycin-resistant enterococci in a tertiary hospital in Turkey | Q44121045 | ||
| Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. | Q44773178 | ||
| Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin | Q44850137 | ||
| TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens | Q46121561 | ||
| Methicillin-resistant Staphylococcus aureus disease in three communities | Q46426018 | ||
| Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. | Q46433642 | ||
| Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent. | Q53439713 | ||
| The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. | Q54441462 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001 | Q56898125 | ||
| Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
| Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence | Q33371390 | ||
| Emergence of vancomycin-resistant enterococci at a university hospital in Taiwan: persistence of multiple species and multiple clones. | Q33805805 | ||
| Epidemiology and susceptibility of 3,051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study | Q33973732 | ||
| Linezolid: the first oxazolidinone antimicrobial | Q34170643 | ||
| Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene | Q34188059 | ||
| Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics | Q34189984 | ||
| Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. | Q34529205 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci | Q34928138 | ||
| In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent | Q34986954 | ||
| In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model | Q35065908 | ||
| Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat | Q36108084 | ||
| High-level vancomycin-resistant enterococci causing hospital infections | Q36473265 | ||
| New oxazolidinones | Q36967558 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 515-522 | |
| P577 | publication date | 2012-02-13 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Tedizolid (TR-701): a new oxazolidinone with enhanced potency | |
| P478 | volume | 21 |
| Q41789967 | An azido-oxazolidinone antibiotic for live bacterial cell imaging and generation of antibiotic variants |
| Q38133967 | Antibiotics in the clinical pipeline in 2013. |
| Q38241139 | Antimicrobial stewardship and linezolid |
| Q52659763 | Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations. |
| Q47684025 | Construction and evaluation in vitro and in vivo of tedizolid phosphate loaded cationic liposomes |
| Q39067666 | Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections |
| Q38123255 | Current and prospective treatments for multidrug-resistant gram-positive infections. |
| Q38123247 | Current strategies for the treatment of complicated intraabdominal infections |
| Q38121142 | Emerging drugs on methicillin-resistant Staphylococcus aureus |
| Q46304818 | In Vitro Susceptibility Testing of Tedizolid against Isolates of Nocardia |
| Q40283050 | In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria |
| Q40525718 | In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China |
| Q34375204 | Investigational antimicrobial agents of 2013. |
| Q26780246 | Investigational drugs to treat methicillin-resistant Staphylococcus aureus |
| Q33438834 | Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections |
| Q34596658 | Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment |
| Q38958278 | Recent Advances in the Rational Design and Optimization of Antibacterial Agents |
| Q24561509 | Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections |
| Q34660917 | Tedizolid: a new oxazolidinone antimicrobial. |
| Q38352171 | Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. |
| Q99633705 | Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses |
| Q38522574 | Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections |
Search more.